AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer – UroToday
|
AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer
UroToday He noted that immunotherapy is an exciting and well-tolerated agent in the treatment of urothelial carcinoma, however, only 15-20% of patients derive significant benefit from this treatment. Bellmunt believes that there are multiple questions that need … |
